Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q1 CY2026, with sales up 4.9% year on year to $16.29 billion. The co...
Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 4.9% year on year to $16....
Global pharmaceutical company Merck (NYSE:MRK) will be reporting results this Thursday before market open. Here’s what investors should know. Merck beat anal...
Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking...
What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a...
Over the past six months, Merck has been a great trade, beating the S&P 500 by 32%. Its stock price has climbed to $118.94, representing a healthy 37.8% incr...
As the first-quarter earnings season of 2026 kicks off, Wall Street is bracing for a high-stakes performance that could determine the trajectory of the market for the remainder of the year. With the S&P 500 projected to deliver a robust 12.6% year-over-year earnings-per-share (EPS) growth, the index is
As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc. (Nasdaq: RVMD) released topline Phase 3 results from its RASolute 302 trial, effectively setting a new standard of care in the treatment of pancreatic cancer. For [...]
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an industry often characterized by volatile "one-hit wonders" and aggressive M&A cycles, Regeneron has carved out a unique identity as a founder-led, R&D-centric powerhouse. Currently, [...]
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...
In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total consideration of up to $5 billion. This strategic maneuver, consisting of $3.15 billion in upfront cash and
Today's Date: April 9, 2026 Introduction In the high-stakes arena of biotechnology, few companies have undergone a transformation as dramatic as ImmunityBio, Inc. (NASDAQ: IBRX). Long viewed by Wall Street as a speculative "story stock" with a complex corporate structure, the company has pivoted sharply into a commercial powerhouse. As of early 2026, ImmunityBio is [...]
BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster anti-PD-1 therapy, KEYTRUDA, as a treatment for certain patients with recurrent ovarian cancer. Announced today, April 2, 2026, the approval targets
